Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...
ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.
VANCOUVER, British Columbia, Dec. 31, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) ("VERSES'' or the ...
VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) ("VERSES' or the "Company"), a cognitive computing company specializing in next generation intelligent ...
Last month the International Energy Agency scrapped its forecast for peak coal consumption, saying use of the world’s ...
Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.
AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven ...
The S&P 500's returns are measured using time-weighted returns (TWR), which don't account for cash flows like withdrawals. If you're retired and withdrawing funds, comparing your portfolio to the S&P ...
As 2024 ends, India’s AI sector has transitioned from its experimentation stage to strategic adoption, primarily driven by ...
Signals from the incoming administration indicate a possible focus on policy pivots that they believe will result in a more ...
As with any technological advancement, there are problems with current artificial intelligence systems. According to VERSES ...
At the January 2025 reinsurance renewals broking group Howden estimates that risk-adjusted pricing for property catastrophe ...